06 January 2004
Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B™ vaccine
Kazimierz Madaliński, Staffan P.E. Sylvan, Ulla Hellström, Jolanta Mikołajewicz, Katarzyna Dzierżanowska-FangratMed Sci Monit 2004; 10(1): PI10-17 :: ID: 11551
Abstract
Background:An advantage of the third-generation HBV vaccines containing preS1 and preS2 antigens was suggested by their excellent immunogenicity in humans and the rapid onset of antibody response to the S-protein of the vaccine. Sequential studies of the antibody responses to the preS1 and preS2 in relation to the anti-HBs response after immunization with preS-containing vaccines have been made in older children only.Material/Methods: Twenty-eight randomly selected, healthy newborns received either 2.5 Kg or 5 Kg of Bio-Hep-B™ (preS1, 2+S) vaccine. The children received 3 doses of vaccine according to a 0, 1, 6 months scheme. Antibodies were determined at months 6 and 9.Results: The vaccine was well tolerated and safe in newborns. Seroconversion and seroprotection were achieved in 100% of newborns after the second injection. No dose-related effect on the anti-HBs response could be observed; GMTs of anti-HBs antibodies after the 2.5 Kg and 5.0 Kg doses were 6703 and 7104 Kg IU/l, respectively. The induction of measurable levels of antibodies towards preS1- and/or preS2-antigens with 2.5 Kg and 5 Kg doses of the vaccine was noted in 29% and 50% of the newborns, respectively, at 6 and/or 9 months of vaccination. An augmented anti-HBs response was elicited in the newborns who produced anti-preS2 after vaccination with 2.5 Kg compared with 5.0 Kg of the vaccine.Conclusions: The vaccine Bio-Hep-B™ can elicit high titers of anti-HBs antibodies in newborns after only two injections. The response of newborns was directed against preS1 + preS2, or preS2 alone.
Keywords: Hepatitis B Antibodies - blood, Hepatitis B Surface Antigens - immunology, Hepatitis B Vaccines - administration & dosage, Hepatitis B Vaccines - adverse effects, Hepatitis B Vaccines - immunology, Immunization Schedule, Infant, Newborn, Protein Precursors - immunology, Hepatitis B Antibodies - blood, Hepatitis B Surface Antigens - immunology, Hepatitis B Vaccines - immunology, Immunization Schedule, Infant, Newborn, Protein Precursors - immunology
Editorial
01 December 2024 : Editorial
Editorial: The 2024 Revision of the Declaration of Helsinki and its Continued Role as a Code of Ethics to Guide Medical ResearchDOI: 10.12659/MSM.947428
Med Sci Monit 2024; 30:e947428
In Press
Clinical Research
Evaluating Lipiodol Efficacy in Proximal Tubal Occlusion Treatment: Single-Center Experience and Literature...Med Sci Monit In Press; DOI: 10.12659/MSM.946266
Review article
Impact of Traditional Chinese Medicine Antioxidants on Oxidative Stress and Drug-Induced Liver Injury: A Re...Med Sci Monit In Press; DOI: 10.12659/MSM.945147
Meta-Analysis
Reliability of Extraoral Scanners in Capturing 3D Geometry for Dental Prostheses: A Systematic ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.946470
Review article
Skin Barrier Dysfunction in Acne Vulgaris: Pathogenesis and Therapeutic ApproachesMed Sci Monit In Press; DOI: 10.12659/MSM.945336
Most Viewed Current Articles
17 Jan 2024 : Review article 6,957,034
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,969,335
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 697,010
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 263,050
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074